{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:55:34Z","timestamp":1777564534192,"version":"3.51.4"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.lungcan.2016.04.024","type":"journal-article","created":{"date-parts":[[2016,5,3]],"date-time":"2016-05-03T16:13:47Z","timestamp":1462292027000},"page":"99-104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"special_numbering":"C","title":["Sunitinib in patients with advanced thymic malignancies: Cohort from the French RYTHMIC network"],"prefix":"10.1016","volume":"97","clinical-trial-number":[{"clinical-trial-number":"nct01621568","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02214134","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Jordi","family":"Remon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Girard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Mazieres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Dansin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Pichon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Grellier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Dubos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colin R","family":"Lindsay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Besse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2016.04.024_bib0005","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/JTO.0b013e31818e105c","article-title":"Thymoma: a focus on current therapeutic management","volume":"4","author":"Girard","year":"2009","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2016.04.024_bib0010","doi-asserted-by":"crossref","first-page":"S260","DOI":"10.1097\/JTO.0b013e3181f1f62d","article-title":"Epidemiology of thymoma and associated malignancies","volume":"5","author":"Engels","year":"2010","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2016.04.024_bib0015","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ejcts.2009.05.038","article-title":"Thymoma and thymic carcinoma","volume":"37","author":"Venuta","year":"2010","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"10.1016\/j.lungcan.2016.04.024_bib0020","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/JTO.0b013e318276241c","article-title":"Thymoma: a population-based study of the management and outcomes for the province of British Columbia","volume":"8","author":"Mariano","year":"2013","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2016.04.024_bib0025","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejca.2007.11.004","article-title":"Thymic epithelial tumours: a population-based study of the incidence, diagnostic procedures and therapy","volume":"44","author":"de Jong","year":"2008","journal-title":"Eur. J. Cancer"},{"issue":"Suppl 5","key":"10.1016\/j.lungcan.2016.04.024_bib0030","doi-asserted-by":"crossref","first-page":"v40","DOI":"10.1093\/annonc\/mdv277","article-title":"ESMO guidelines committee, thymic epithelial tumours: eSMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Girard","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2016.04.024_bib0035","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00432-014-1800-6","article-title":"Key components of chemotherapy for thymic malignancies: a systematic review and pooled analysis for anthracycline-, carboplatin- or cisplatin-based chemotherapy","volume":"141","author":"Okuma","year":"2015","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2016.04.024_bib0040","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.lungcan.2014.05.010","article-title":"Thymic epithelial tumors express vascular endothelial growth factors and their receptors as potential targets of antiangiogenic therapy: a tissue micro array-based multicenter study","volume":"85","author":"Lattanzio","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2016.04.024_bib0045","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.aanat.2007.05.003","article-title":"Immunohistochemical expression of vascular endothelial growth factor A (VEGF), and its receptors (VEGFR1, 2) in normal and pathologic conditions of the human thymus","volume":"190","author":"Cimpean","year":"2008","journal-title":"Ann. Anat."},{"key":"10.1016\/j.lungcan.2016.04.024_bib0050","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1007\/s005950170021","article-title":"Elevated serum vascular endothelial growth factor and basic fibroblast growth factor levels in patients with thymic epithelial neoplasms","volume":"31","author":"Sasaki","year":"2001","journal-title":"Surg. Today"},{"key":"10.1016\/j.lungcan.2016.04.024_bib0055","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1067\/mtc.2002.124389","article-title":"Correlation between tumor angiogenesis and invasiveness in thymic epithelial tumors","volume":"124","author":"Tomita","year":"2002","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.lungcan.2016.04.024_bib0060","article-title":"A phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma","author":"Bedano","year":"2015","journal-title":"ASCO Meet."},{"issue":"suppl. 2","key":"10.1016\/j.lungcan.2016.04.024_bib0065","article-title":"Legrand f, robert R, Therasse P, Soria J, Clinical activity of lucitanib in advanced thymic epithelial tumors","volume":"9","author":"Besse","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2016.04.024_bib0070","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1182\/blood-2002-07-2307","article-title":"SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo","volume":"101","author":"O\u2019Farrell","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.lungcan.2016.04.024_bib0075","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1470-2045(14)71181-7","article-title":"Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial","volume":"16","author":"Thomas","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2016.04.024_bib0080","doi-asserted-by":"crossref","first-page":"S1710","DOI":"10.1097\/JTO.0b013e31821e8cff","article-title":"The Masaoka-Koga stage classification for thymic malignancies: clarification and definition of terms","volume":"6","author":"Detterbeck","year":"2011","journal-title":"J. Thorac. Oncol."},{"issue":"2015","key":"10.1016\/j.lungcan.2016.04.024_bib0085","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1097\/JTO.0000000000000654","article-title":"The 2015 world health organization classification of tumors of the thymus: continuity and changes","volume":"10","author":"Marx","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2016.04.024_bib0090","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.lungcan.2016.04.024_bib0095","series-title":"Common Terminology Criteria for Adverse Events v.3.0 and v.4.0 (CTCAE)","author":"National Cancer Institute","year":"2015"},{"issue":"suppl. 2","key":"10.1016\/j.lungcan.2016.04.024_bib0100","first-page":"449","article-title":"Pan-European survey on thymic malignancies: a collaboration of the EORTC lung cancer group (LCG) with the RYTHMIC network","volume":"9","author":"Menis","year":"2015","journal-title":"J Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2016.04.024_bib0105","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.lungcan.2014.11.006","article-title":"Pemetrexed in patients with thymic malignancies previously treated with chemotherapy","volume":"87","author":"Liang","year":"2015","journal-title":"Lung Cancer"},{"issue":"Suppl 3","key":"10.1016\/j.lungcan.2016.04.024_bib0110","article-title":"Oral 1. 01: Phase II trial of amrubicin in patients with previously treated advanced thymic malignancies","volume":"7","author":"Wakelee","year":"2015","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.lungcan.2016.04.024_bib0115","first-page":"39","article-title":"oral etoposide in pretreated advanced thymoma and thymic carcinoma. a french experience","volume":"8","author":"Boutros","year":"2013","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2016.04.024_bib0120","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.2217\/fon.14.144","article-title":"Capecitabine plus gemcitabine in thymic epithelial tumors: final analysis of a Phase II trial","volume":"10","author":"Palmieri","year":"2014","journal-title":"Future Oncol."},{"key":"10.1016\/j.lungcan.2016.04.024_bib0125","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.clgc.2014.11.004","article-title":"Efficacy and safety of an attenuated-Dose sunitinib regimen in metastatic renal cell carcinoma: results from a prospective registry in Singapore","volume":"13","author":"Tan","year":"2015","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.lungcan.2016.04.024_bib0130","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.urolonc.2015.03.008","article-title":"Sunitinib dosing schedule 2\/1 improves tolerability, efficacy, and health-related quality of life in Chinese patients with metastatic renal cell carcinoma","volume":"33","author":"Pan","year":"2015","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.lungcan.2016.04.024_bib0135","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/path.1514","article-title":"KIT. (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas","volume":"202","author":"Pan","year":"2004","journal-title":"J. Pathol."},{"key":"10.1016\/j.lungcan.2016.04.024_bib0140","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.lungcan.2008.03.013","article-title":"Mutational status of EGFR and KIT in thymoma and thymic carcinoma","volume":"62","author":"Yoh","year":"2008","journal-title":"Lung Cancer."},{"key":"10.1016\/j.lungcan.2016.04.024_bib0145","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1093\/annonc\/mdr626","article-title":"Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors","volume":"23","author":"Schirosi","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2016.04.024_bib0150","doi-asserted-by":"crossref","first-page":"6790","DOI":"10.1158\/1078-0432.CCR-09-0644","article-title":"Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas","volume":"15","author":"Girard","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2016.04.024_bib0155","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/sj.bjc.6605740","article-title":"Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience","volume":"103","author":"Str\u00f6bel","year":"2010","journal-title":"Br. J. Cancer."},{"key":"10.1016\/j.lungcan.2016.04.024_bib0160","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1200\/JCO.2014.58.2007","article-title":"Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial","volume":"33","author":"Lopez-Chavez","year":"2015","journal-title":"J. Clin. Oncol."}],"updated-by":[{"DOI":"10.1016\/j.lungcan.2016.09.014","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000}}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500216303105?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500216303105?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:22:25Z","timestamp":1759234945000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500216303105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":32,"alternative-id":["S0169500216303105"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2016.04.024","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.lungcan.2016.09.014","asserted-by":"object"}]},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sunitinib in patients with advanced thymic malignancies: Cohort from the French RYTHMIC network","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2016.04.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}